Search by:

You are here

One step closer to a diagnosis for Alzheimer's

McGill University researchers work with pharmaceutical company to develop a reliable diagnostic tool for the most common form of dementia
January 3, 2013

The annual cost of dementia to society has been estimated at about $15 billion a year, a figure that is expected to increase ten-fold over the next 25 years, when approximately 1.1 million Canadians will be living with the condition. With just over two-thirds of that group likely to suffer from Alzheimer’s, finding a diagnostic tool is crucial. 

Investigators at the Research Institute of the McGill University Health Centre have discovered lower levels of a brain hormone precursor in the blood of patients affected by Alzheimer’s compared to those who are not. They are working with Samaritan Pharmaceuticals and Samaritan Therapeutics to develop a simple, reliable blood test to diagnose Alzheimer’s, perhaps even before any symptoms are apparent.